Sentence examples for pathway blocker from inspiring English sources

Nevertheless, our present data still indicate a possibility of an ER α pathway blocker as a therapeutic tool for patients with ER α-positive gastric cancer.

Apoptosis in the femoral head was evaluated after the animals were administered sFRP1, which is a Wnt/β-catenin pathway blocker.

To investigate the impact of FOXA1 on the AR-mediated transcription, the AR pathway agonist 5α-dihydrotestosterone (DHT) (Dr. Ehrenstorfer, Augsburg, Germany) and the AR pathway blocker flutamide (Sigma) were purchased and dissolved in 100% ethanol for storage.

The TLR signaling pathway blocker GIT27 may have clinical potential and is very attractive, as, unlike the well-known antibiotic with high LPS-binding capacity, polymyxin b sulfate, GIT27 seems not to be nephrotoxic.

The BMP signaling antagonist dorsomorphin induces cardiomyocyte differentiation in mouse ESCs (79), and the TGFβ pathway blocker SD-208 promotes hematopoiesis and alleviates anemia in a mouse model of myelodysplastic syndrome, a disease caused by the constitutive activation of ALK5 in bone marrow precursors (80).

Although these results are encouraging, there are few if any complete or durable responses to either sorafenib or the other VEGF pathway blockers.

Subsequently the VEGF pathway blockers sunitinib, bevacizumab and pazopanib were also shown to have sufficient benefit in patients with advanced RCC to merit FDA approval [3].

The inability to sustain the initial tumor stabilization or regression induced by VEGF pathway blockers is arguably the most vexing problem now encountered by oncologists who care for patients with RCC.

In particular, higher response rates and longer PFS have been reported for patients receiving other VEGF pathway blockers, e.g. axitinib after disease progression on sorafenib, or sunitinib after disease progression on bevacizumab [3], [5] [6].

These hypotheses are supported by clinical observations of antitumor activity seen with 1) sequential administration of VEGF pathway blockers [5], [19] 2) rechallenge with sunitinib after a drug holiday [20], 3) evidence from the recently reported EFFECT trial that intermittent sunitinib therapy produces superior efficacy than continuous therapy [21].

Finding small molecules that would act as pathway blockers has attracted much therapeutic interest but so far there are no available WNT-TCF blockers in the clinics, partly due to the time and cost of developing new drugs.